DOCSLIB.ORG

Iv2001 Lrs.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Iv2001 Lrs.Pdf VOLUME 38 NUMBER 01 JANUARY 2020 Connected Strategies Are A Tale Of Two Pipelines AstraZeneca’s Fredrickson Vital For Medtechs In 2020 On Its Cancer Ambitions PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ January 2020 8 COVER ❚ In 2020 ESG Is Not A Tick-Box Exercise But An Opportunity William Looney The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business. 14 20 24 A Tale Of Two Pipelines Bayer US Pharmaceuticals’ Connected Strategies Are Vital DENNIS CHANG, KEITH FLAHERTY AND Sebastian Guth: Designs On For Medtechs In The Consumer- UCIANE SCARLETT A New Decaden Led 2020s Immuno-oncology has produced some WILLIAM LOONEY ASHLEY YEO exciting successes, but the field has Bayer’s ambitious campaign to Discussions on the shape of health care become intensely crowded. Enormous reposition itself as a global leader in two have moved from “reimagining” to the resources are being poured into complementary fields – health and next stage: building and executing on the duplicative work and shaky hypotheses— nutrition – will face its toughest test in vision. That is the thrust of EY’s NextWave overshadowing other pursuits in cancer the US, with its highly litigious approach Report: New Horizons 2019. Additionally, research while producing limited results. to product liability and a tendency to for medtechs seeking business continu- It is time to re-evaluate how the sector target pharmaceuticals as the source of um, “duality” is now a preoccupying should be pursuing innovation in cancer the health system’s affordability and thought. and how it can be smarter in its use of access problems. resources—financial investment, talent, bandwidth, patients and data. 30 AstraZeneca's Fredrickson On Its 28 Cancer Ambitions Roche/Genentech Partnering ALEX SHIMMINGS Team: One Face For The World Just over a year ago AstraZeneca at last To See returned to growth and set about a reorganization that placed oncology at the LUCIE ELLIS heart of its plans for continued success. In Thomas Zioncheck, global head of Vivo talked to the executive vice-president neuroscience, ophthalmology and rare of its Oncology Business Unit David diseases, Roche Pharma Partnering, talks SEBASTIAN GUTH Fredrickson about how the company to In Vivo about Roche and Genentech’s hopes to become a major cancer player. united partnering group, 2019 successes, and highlights ahead for the big phar- ma’s neuroscience pipeline. ©2016 Informa Business Information, Inc., an Informa company January 2020 | In Vivo | 1 ❚ CONTENTS January 2020 DEPARTMENTS ❚ From The Editor AROUND THE INDUSTRY In this first issue of a brand-new decade, In Vivo 4 Executive Briefing: C-Suite And has filled its pages with a variety of content, Investors Discuss A New Decade from C-suite interviews to productivity over- WILLIAM MASTERS views and strategy analyses. 6 When Will POC Really Be On At the close of 2019, we published the annual The Cusp Of Major Uptake? Outlook issue which comprises 10 chapters of ASHLEY YEO original content, including the most recent Scrip 100 and Medtech 100 company perfor- 34 ON THE MOVE mance rankings. All of this content can be Recent executive appointments found in one place on our website: invivo.phar- in the life sciences industry LUCIE ELLIS maintelligence.informa.com/outlook. REGINA PALESKI Meanwhile, looking ahead into the new year, we have published a selection of thought leadership articles online that analyze the year ahead, predict- 38 DEAL-MAKING ing key trends and discussing hot topics like gene therapy M&A targets and Deals Shaping The Medical Industry, the advancement of digital tools. December 2019 THE STRATEGIC TRANSACTIONS TEAM The start of 2020 also marks a few changes at In Vivo Headquarters. William Looney has retired from In Vivo, however he will still be involved with the publication as a new member of our Editorial Advisory Board. The advisory board itself is undergoing some changes – look out for exciting announce- EXCLUSIVE ONLINE CONTENT ments about this in our February issue. invivo.pharmaintelligence.informa.com Succeeding William as In Vivo’s executive editor for biopharma is Ben Comer, who joined the team on January 6, 2020. Prior to joining us, Ben was a senior ❚ AstraZeneca Veteran Returns To manager in PwC’s Health Research Institute. Previously, he was a journalist Biotech With Fresh Goals For A with Pharmaceutical Executive; Medical Marketing & Media, PRWeek and Di- New Decade rect Marketing News; and Ad-Fax Media. LUCIE ELLIS Finally, January see us launch the annual Deals Of The Year contest. Voting is open in the three categories for 2019: Top M&A, Top Alliance and Top Fi- ❚ Gene Therapy Companies Among nancing. The winners will be announced in February. Don’t miss your Top M&A Targets In 2020 chance to vote, go to our homepage for full details of the nominees. ANDREW MCCONAGHIE ❚ What Does 2020 Hold For Biopharma? In Vivo: Always Online First Don’t have an online user account? JOSEPH HAAS AND Quickly and easily create one Relevant and exclusive online-only ELEANOR MALONE by clicking on the “Create your content at your fingertips 24/7. account” link at the top of the page. Full access to our 36-year archive. ❚ The Role Of AI In Signal Detection Contact: MIRANDA GREENHALGH Access your subscription by visiting: [email protected] invivo.pharmaintelligence.informa. or call: (888) 670-8900 or +1 (908) ❚ What The New Decade Could Bring com and log in. 748-1221 for additional information. For Alzheimer’s Treatment ANDREA PFEIFER All stock images in this publication courtesy of /invivo @invivo /invivo www.shutterstock.com unless otherwise stated. 2 | | January 2020 invivo.pharmamedtechbi.com In Vivo invivo.pharmaintelligence.informa.com invivo.pharmaintelligence.informa.com CONTENTS ❚ ❚ Up-Front SNAPSHOTS FROM JANUARY’S CONTENT Every partnership is unique, “a rulebook approach is not useful now that the overall climate for drug development is so fast- Given the widely held view paced and competitive” that medicines, devices PAGE 20 and diagnostics are public – Sebastian Guth goods, pharma and medtech companies face a high credibility bar on environmental, social and governance activities. A tremendous amount of It is no longer standard capital and human resources practice to assign the ESG has been consumed by portfolio to the corporate policy team. PAGE 8 immuno-oncology, and there are signs that exuberance for immunotherapy has become The future of health lies “ I want to let partners with technology. Within unsustainable. PAGE 14 2010 2011 2012 2013 2014 2015 know that we’re very the health care industries, 120% open to partnering new investors have been among 100% technologies, across the first to act on this 80% neurodegeneration, realization, funding health 60% tech, practice management 40% neuroinflammation and 20% neuromuscular diseases” and home health care ever 0% PAGE 28 more concertedly over the Amount of royalties/milestones not disclosed – Thomas Zioncheck past decade. PAGE 24 Note: Bubble size represents vale of upfront payment ©2016 Informa Business Information, Inc., an Informa company January 2020 | In Vivo | 3 ❚ Around The Industry Executive Briefing: C-Suite And Investors Discuss A New Decade From the US election to being over-focused on oncology, from the promise of artificial revenue stream. intelligence to private funding in Europe – there were a range of issues and opportuni- “All over the world, especially in the ties discussed at In Vivo’s inaugural executive briefing. emerging markets, they are all running out of money. Health care budgets are Having a commercially relevant drug completely challenged – they haven’t got means having a product that is “afford- any money at all. So even if you go into able and accessible,” said Roel Bulthuis, ❚ PANEL SESSION: specialty pharmaceuticals, if you go into managing director of INKEF Capital. “As BIOPHARMA STATE OF rare diseases, they cost anywhere up to investors, and as an industry, we need PLAY IN 2020 AND BEYOND $2m dollars per patient. Authorities in to take an active role in defining what Brazil, India, South Korea or South Africa affordable means. If we don’t think right cannot afford these things. So, we have now about how we’re going to position CHAIR: to rethink this.” drugs in a commercially relevant setting – Mike Ward, Head of Content Bulthuis defended the idea of having meaning affordable – we’re going to lose at EBD Group different portfolios for different markets, that discretion at some point,” he said. arguing that it is the same for any in- The specter looming over the com- PANELISTS: dustry: “If I were developing software I ment, and the industry itself, is the Roel Bulthuis, MD, would start with where the market was.” current hostile political discourse sur- INKEF Capital Bulthuis made the case that developing rounding drug pricing. When asked by products for the US and Europe was a chair of the panel, Mike Ward, what was Charlotte Casebourne, different thesis than for Africa. He noted keeping the industry up at night in 2020, CEO of Theolytics & that the industry was already increasing four out of six panelists emphasized the board member at BIA investment outside of traditional mar- political climate – including the US elec- kets, moving into East and Southeast tion, Brexit, and the US-China trade war. Tobias Kloepper, CEO, Asia. While agreeing that access and The US still represents around 60% Aigenpulse affordability should rightly be champi- of industry revenues today, noted Zulf oned, Bulthuis argued that to justify an Zulf Masters, CEO, Masters, CEO of Masters Specialty Phar- investment “you have to start with where Masters Specialty Pharma maceuticals.
Load more

Recommended publications
  • United States Atopic Dermatitis (AD) Market Report 2021
    Source: Research and Markets July 28, 2021 04:08 ET United States Atopic Dermatitis (AD) Market Report 2021 Dublin, July 28, 2021 (GLOBE NEWSWIRE) -- The "Atopic Dermatitis (AD) - US Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. This 'Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in- depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the United States. Key Findings The total prevalent population of AD in the United States was estimated to be 32,197,083 in 2020. The total diagnosed prevalent population of AD in the United States was estimated to be 25,091,967 in 2020. The prevalent population of AD in the United States is expected to increase at a CAGR of 0.58% during the study period 2018-2030. In the United States, the total number of adult cases of AD comprised of 5,684,566 males and 9,421,907 females in 2020. The total number of cases of mild AD were 9,065,394 in the United States, in 2020, as compared to the cases of moderate and severe AD with 4,365,771 and 1,661,712 cases respectively, in adults. In children, the total number of cases of mild AD were 6,690,281, in 2020, as compared to the cases of moderate and severe AD with 2,596,228 and 698,985 cases respectively, in the United States. Report Highlights In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
    [Show full text]
  • Inflarx N.V. 2020 Dutch Board Report
    InflaRx N.V. Dutch statutory board report and financial statements for the financial year ended December 31, 2020 - 1 - TABLE OF CONTENTS 1 Introduction ............................................................................................................................... 4 1.1 Preparation ................................................................................................................................. 4 1.2 Forward-looking statements ...................................................................................................... 4 2* Risk factors ................................................................................................................................ 7 2.1 Summary of key risk factors ...................................................................................................... 7 2.2 Risk factors ................................................................................................................................ 7 2.2.1 Risks related to our financial position and need for additional capital. ..................................... 7 2.2.2 Risks related to the discovery, development and commercialization of our product candidates. ................................................................................................................................................... 9 2.2.3 Risks related to our dependence on third parties ..................................................................... 20 2.2.4 Risks related to our intellectual property ................................................................................
    [Show full text]
  • Conference Reportpeer-Reviewed
    Medicom International Conference Series in Dermatology 28th EADV Congress European Academy of Dermatology and Venereology 9-13 october 2019 • Madrid • Spain EVIEWED R PEER- CONFERENCE CONFERENCE REPORT Late-Breaking News Emerging Therapies Spotlight on Psoriasis JAK inhibitors are a fascinating The IL-4/IL-13 blocker dupilumab Ten-year data from the ESPRIT novel drug class entering the der- leads to rapid itch reduction in registry shows the importance of matologic arena. The JAK1 and adolescents. The safety profile is achieving good control of moderate- JAK2 inhibitor baricitinib showed similar to that in adults. to-severe psoriasis. to be effective in patients with moderate-to-severe atopic derma- titis in a phase 3 trial. read more on PAGE 5 read more on PAGE 10 read more on PAGE 13 Editor Peter van de Kerkhof, Radboud University Medical Center, the Netherlands MEDIC AL PUBLISHERS Contents Letter from the Editor 3 Late-Breaking News 3 IL-17A blocker effective in paediatric psoriasis patients 3 Rituximab beats mycophenolate mofetil in pemphigus vulgaris COLOPHON 4 Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata Editor Prof. Peter van de Kerkhof Radboud University Medical Center, 5 Acne highly influenced by climate, pollutants, and unhealthy diet the Netherlands 5 JAK inhibition plus TCS lead to high clearance rates in AD Advisory Board Prof. Margarida Gonçalo 6 No cancer risk with long-term use of calcineurin inhibitor in Coimbra University Hospital, Portugal children with AD Dr Tom Hillary UZ Leuven, Belgium 7 Green
    [Show full text]
  • Atopic Dermatitis: an Expanding Therapeutic Pipeline for a Complex Disease
    REVIEWS Atopic dermatitis: an expanding therapeutic pipeline for a complex disease Thomas Bieber 1,2,3 Abstract | Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates. In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti- IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease. Atopic disorders Atopic dermatitis (AD) is the most common chronic inhibitors tacrolimus and pimecrolimus and more 1,2 A group of disorders having in inflammatory skin disease . About 80% of disease cases recently the phosphodiesterase 4 (PDE4) inhibitor cris- common a genetic tendency to typically start in infancy or childhood, with the remain- aborole. For the more severe forms of AD, besides the develop IgE- mediated allergic der developing during adulthood. Whereas the point use of ultraviolet light, current therapeutic guidelines reactions. These are atopic dermatitis, food allergy, allergic prevalence in children varies from 2.7% to 20.1% across suggest ciclosporin A, methotrexate, azathioprine and 3,4 rhino- conjunctivitis and countries, it ranges from 2.1% to 4.9% in adults .
    [Show full text]
  • Frontiers in Dermatology and Venereology - a Series of Theme Issues in Relation to the 100-Year Anniversary of Actadv
    ISSN 0001-5555 ActaDV Volume 100 2020 Theme issue ADVANCES IN DERMATOLOGY AND VENEREOLOGY A Non-profit International Journal for Interdisciplinary Skin Research, Clinical and Experimental Dermatology and Sexually Transmitted Diseases Frontiers in Dermatology and Venereology - A series of theme issues in relation to the 100-year anniversary of ActaDV Official Journal of - European Society for Dermatology and Psychiatry Affiliated with - The International Forum for the Study of Itch Immediate Open Access Acta Dermato-Venereologica www.medicaljournals.se/adv ACTA DERMATO-VENEREOLOGICA The journal was founded in 1920 by Professor Johan Almkvist. Since 1969 ownership has been vested in the Society for Publication of Acta Dermato-Venereologica, a non-profit organization. Since 2006 the journal is published online, independently without a commercial publisher. (For further information please see the journal’s website https://www. medicaljournals.se/acta) ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes high- quality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times. Editor-in-Chief: Olle Larkö, MD, PhD, Gothenburg Former Editors: Johan Almkvist 1920–1935 Deputy Editors: Sven Hellerström 1935–1969
    [Show full text]
  • Hidradenitis Suppurativa: Where We Are and Where We Are Going
    cells Review Hidradenitis Suppurativa: Where We Are and Where We Are Going Emanuele Scala 1,* , Sara Cacciapuoti 2 , Natalie Garzorz-Stark 1,3, Matteo Megna 2 , Claudio Marasca 2, Peter Seiringer 1,4, Thomas Volz 3, Kilian Eyerich 1,3,5,† and Gabriella Fabbrocini 2,† 1 Division of Dermatology and Venereology, Department of Medicine Solna and Center for Molecular Medicine, Karolinska Institutet, 17176 Stockholm, Sweden; [email protected] (N.G.-S.); [email protected] (P.S.); [email protected] (K.E.) 2 Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy; [email protected] (S.C.); [email protected] (M.M.); [email protected] (C.M.); [email protected] (G.F.) 3 Department of Dermatology and Allergy, Technical University of Munich, 80802 Munich, Germany; [email protected] 4 Center for Allergy and Environment, Technical University, Helmholtz Center Munich, 80802 Munich, Germany 5 Unit of Dermatology, Department of Dermatology and Venereology, Karolinska University Hospital, 17176 Stockholm, Sweden * Correspondence: [email protected] † These authors contributed equally to the manuscript. Abstract: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. It is a multifactorial disease in which genetic and environmental factors play a key role. The primary defect in HS pathophysiology involves follicular occlusion Citation: Scala, E.; Cacciapuoti, S.; of the folliculopilosebaceous unit, followed by follicular rupture and immune responses. Innate Garzorz-Stark, N.; Megna, M.; pro-inflammatory cytokines (e.g., IL-1β, and TNF-α); mediators of activated T helper (Th)1 and Th17 Marasca, C.; Seiringer, P.; Volz, T.; cells (e.g., IFN-γ, and IL-17); and effector mechanisms of neutrophilic granulocytes, macrophages, Eyerich, K.; Fabbrocini, G.
    [Show full text]
  • Aars Hot Topics Member Newsletter
    AARS HOT TOPICS MEMBER NEWSLETTER American Acne and Rosacea Society 201 Claremont Avenue • Montclair, NJ 07042 (888) 744-DERM (3376) • [email protected] www.acneandrosacea.org Like Our YouTube Page Visit acneandrosacea.org to Become an AARS Member and TABLE OF CONTENTS Donate Now on acneandrosacea.org/donate Industry News Mederma survey: America's got skin insecurities. ...................................................... 2 Our Officers Accure Acne seeks to raise up to $20 million through private placement offering ..... 2 J. Mark Jackson, MD AARS President New Medical Research Scientifically speaking: New directions in acne management, part 1. ........................ 3 Andrea Zaenglein, MD Tranexamic acid microinjections ................................................................................. 3 AARS President-Elect An increase in normetanephrine in hair follicles of acne lesions ................................ 4 Effects of ısotretinoin on the growth rate and thickness of the nail plate .................... 4 Joshua Zeichner, MD The effectiveness of botulinum toxin type A (BTX-A) in the treatment of facial skin .. 4 AARS Treasurer Efficacy and safety of non-surgical short-wave radiofrequency treatment ................. 5 Incidence and clinical implications of autoimmune thyroiditis ..................................... 5 Bethanee Schlosser, MD Topical 15% resorcinol is associated with high treatment satisfaction ....................... 6 AARS Secretary A novel azelaic acid formulation for the topical treatment of inflammatory
    [Show full text]
  • Personalized Medicine—Concepts, Technologies, and Applications in Inflammatory Skin Diseases
    Personalized medicine - concepts, technologies, and applications in inflammatory skin diseases Litman, T. Published in: APMIS - Journal of Pathology, Microbiology and Immunology DOI: 10.1111/apm.12934 Publication date: 2019 Document version Publisher's PDF, also known as Version of record Document license: CC BY Citation for published version (APA): Litman, T. (2019). Personalized medicine - concepts, technologies, and applications in inflammatory skin diseases. APMIS - Journal of Pathology, Microbiology and Immunology, 127(5), 386-424. https://doi.org/10.1111/apm.12934 Download date: 09. apr.. 2020 JOURNAL OF PATHOLOGY, MICROBIOLOGY AND IMMUNOLOGY APMIS 127: 386–424 © 2019 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Medical Microbiology and Pathology. DOI 10.1111/apm.12934 Review Article Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases THOMAS LITMAN1,2 1Department of Immunology and Microbiology, University of Copenhagen, Copenhagen; 2Explorative Biology, Skin Research, LEO Pharma A/S, Ballerup, Denmark Litman T. Personalized medicine—concepts, technologies, and applications in inflammatory skin diseases. APMIS 2019; 127: 386–424. The current state, tools, and applications of personalized medicine with special emphasis on inflammatory skin diseases like psoriasis and atopic dermatitis are discussed. Inflammatory pathways are outlined as well as potential targets for monoclonal antibodies and small-molecule inhibitors. Key words: Atopic dermatitis; endotypes; immunology; inflammatory skin diseases; personalized medicine; precision medicine; psoriasis; targeted therapy. Thomas Litman, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. e-mail: [email protected] and Explorative Biology, Skin Research, LEO Pharna A/S, Ballerup, Denmark. e-mail: [email protected] INTRODUCTION – WHY? proteins (4, 5).
    [Show full text]
  • Lääkeaineiden Yleisnimet (INN-Nimet) 21.6.2021
    Lääkealan turvallisuus- ja kehittämiskeskus Säkerhets- och utvecklingscentret för läkemedelsområdet Finnish Medicines Agency Lääkeaineiden yleisnimet (INN-nimet) 21.6.
    [Show full text]
  • Inflarx N.V. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001-38283 InflaRx N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Jurisdiction of incorporation or organization) Winzerlaer Str. 2 07745 Jena, Germany (+49) 3641 508 180 (Address of principal executive offices) Dr. Thomas Taapken, Chief Financial Officer Tel: (+49) 89 4141 897 800 Fraunhoferstr. 22, 82152 Planegg-Martinsried, Germany (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Copies to: Sophia Hudson Kirkland & Ellis LLP 601 Lexington Avenue New York, NY 10022 Phone: (212) 446-4750 Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, nominal value €0.12 per share IFRX The NASDAQ Stock Market LLC Securities registered or to be registered pursuant to Section 12(g) of the Act: None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.
    [Show full text]
  • NETTER, Jr., Robert, C. Et Al.; Dann, Dorf- (21) International Application
    ll ( (51) International Patent Classification: (74) Agent: NETTER, Jr., Robert, C. et al.; Dann, Dorf- C07K 16/28 (2006.01) man, Herrell and Skillman, 1601 Market Street, Suite 2400, Philadelphia, PA 19103-2307 (US). (21) International Application Number: PCT/US2020/030354 (81) Designated States (unless otherwise indicated, for every kind of national protection av ailable) . AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 29 April 2020 (29.04.2020) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (26) Publication Language: English KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (30) Priority Data: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/840,465 30 April 2019 (30.04.2019) US OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicants: INSTITUTE FOR CANCER RESEARCH TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER [US/US]; 333 Cottman Av¬ (84) Designated States (unless otherwise indicated, for every enue, Philadelphia, PA 191 11-2497 (US). UNIVERSTIY kind of regional protection available) . ARIPO (BW, GH, OF KANSAS [US/US]; 245 Strong Hall, 1450 Jayhawk GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Boulevard, Lawrence, KS 66045 (US).
    [Show full text]
  • Topical and Systematic Treatment of Atopic Dermatitis to Inform a Clinical Practice Guideline
    Topical and Systemic Treatment of Atopic Dermatitis Results of Topic Selection Process & Next Steps The nominator American Academy of Dermatology, is interested in a new evidence review on Topical and Systematic Treatment of Atopic Dermatitis to inform a clinical practice guideline. We identified several review(s) covering part of the scope of the nomination, therefore, a new review would be partially duplicative of an existing product. For the questions not covered by existing reviews, there is limited original research. No further activity on this nomination will be undertaken by the Effective Health Care (EHC) Program. Topic Brief Topic Numbers and Name: #0804, 0805, 0806 Topical and Systemic Treatment of Atopic Dermatitis Nomination Date: 7/09/2018 Topic Brief Date: 10/11/2018 Authors Elise Berliner Conflict of Interest: None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report. 1 Background Atopic dermatitis is a common chronic skin condition that causes itchy scaly red patches. The 1-year US prevalence of AD was estimated at 12.98% in children in 2007-2008 and 7.2%-10.2% in adults in 2010-20121. There is no biomarker, objective diagnostic test, or even standard nomenclature for describing atopic dermatitis and related conditions such as other forms of eczema. NIH has funded an initiative to harmonize outcome measures in atopic dermatitis.2 Patients with atopic dermatitis typically try to control their symptoms through supportive care including bathing and moisturizing ointments, wearing soft breathable fabrics and avoiding contact with allergens. The current American Academy of Dermatology guidelines do not recommend non-sedating antihistamines for atopic dermatitis, but recognize that sedating antihistamines may have value in controlling insomnia secondary to itching.
    [Show full text]